AAPL321.61+6.29 (+1.99%) ▲|ABBV247.78-0.31 (-0.12%) ▼|ABT92.38-1.55 (-1.65%) ▼|ACN136.61+1.38 (+1.02%) ▲|ADBE227.17+3.53 (+1.58%) ▲|AMAT579.00-23.50 (-3.90%) ▼|AMD533.01-24.88 (-4.46%) ▼|AMGN359.68-3.71 (-1.02%) ▼|AMT169.91+1.32 (+0.78%) ▲|AMZN246.52+1.18 (+0.48%) ▲|AVGO390.93-9.05 (-2.26%) ▼|AXP355.80+5.22 (+1.49%) ▲|BA217.87-4.42 (-1.99%) ▼|BAC59.06-0.62 (-1.03%) ▼|BKNG176.69-1.70 (-0.95%) ▼|BLK1,026.15-9.96 (-0.96%) ▼|BMY58.48+0.90 (+1.55%) ▲|BNY150.54-1.38 (-0.91%) ▼|BRK-B499.05+5.34 (+1.08%) ▲|C138.54-2.25 (-1.60%) ▼|CAT938.96-13.46 (-1.41%) ▼|CL93.47+1.23 (+1.33%) ▲|CMCSA24.10+0.53 (+2.23%) ▲|COF203.45+1.93 (+0.96%) ▲|COP111.34+2.30 (+2.11%) ▲|COST919.22+2.97 (+0.32%) ▲|CRM166.51+3.19 (+1.95%) ▲|CSCO118.05-3.26 (-2.69%) ▼|CVS106.10+1.95 (+1.87%) ▲|CVX179.77+3.37 (+1.91%) ▲|DE583.31-3.56 (-0.61%) ▼|DHR199.62+0.57 (+0.29%) ▲|DIS97.22+1.60 (+1.67%) ▲|DUK126.93+1.45 (+1.16%) ▲|EMR138.32-0.57 (-0.41%) ▼|FDX314.44-0.25 (-0.08%) ▼|GD375.81+0.75 (+0.20%) ▲|GE356.69-2.58 (-0.72%) ▼|GEV1,062.11-29.47 (-2.70%) ▼|GILD129.23-0.61 (-0.47%) ▼|GM77.71-0.15 (-0.19%) ▼|GOOG353.36-1.68 (-0.47%) ▼|GOOGL355.78-1.40 (-0.39%) ▼|GS1,052.16-3.02 (-0.29%) ▼|HD343.29-0.01 (0.00%) ▼|HON222.88-3.55 (-1.57%) ▼|IBM292.22+4.66 (+1.62%) ▲|INTC105.02-4.82 (-4.39%) ▼|INTU284.76+9.80 (+3.56%) ▲|ISRG412.72+5.94 (+1.46%) ▲|JNJ257.41+0.43 (+0.17%) ▲|JPM334.44-2.03 (-0.60%) ▼|KO84.18+0.69 (+0.83%) ▲|LIN526.02-3.77 (-0.71%) ▼|LLY1,189.15+0.57 (+0.05%) ▲|LMT520.15-3.08 (-0.59%) ▼|LOW212.21+0.58 (+0.27%) ▲|LRCX333.32-17.01 (-4.86%) ▼|MA534.50+7.76 (+1.47%) ▲|MCD274.49-0.12 (-0.04%) ▼|MDLZ60.47+1.64 (+2.79%) ▲|MDT84.40+0.53 (+0.63%) ▲|META663.80-5.41 (-0.81%) ▼|MMM158.57+1.05 (+0.67%) ▲|MO72.74+0.95 (+1.32%) ▲|MRK123.71+0.17 (+0.14%) ▲|MS220.66-1.62 (-0.73%) ▼|MSFT385.60+0.50 (+0.13%) ▲|MU930.45-48.86 (-4.99%) ▼|NEE88.39+0.43 (+0.48%) ▲|NFLX75.22+1.85 (+2.51%) ▲|NKE44.45+0.08 (+0.17%) ▲|NOW108.55+0.84 (+0.78%) ▲|NVDA209.34-1.62 (-0.77%) ▼|ORCL136.14-4.51 (-3.20%) ▼|PEP139.75+2.37 (+1.73%) ▲|PFE24.63+0.46 (+1.88%) ▲|PG149.10+2.06 (+1.40%) ▲|PLTR128.28+1.49 (+1.18%) ▲|PM182.80+1.18 (+0.65%) ▲|QCOM186.37-2.79 (-1.47%) ▼|RTX195.83-0.10 (-0.05%) ▼|SBUX107.98+1.97 (+1.86%) ▲|SCHW102.72-0.40 (-0.39%) ▼|SO96.63+1.02 (+1.06%) ▲|SPG221.45+2.68 (+1.22%) ▲|T21.44+0.31 (+1.44%) ▲|TMO528.36+1.31 (+0.25%) ▲|TMUS189.88+2.27 (+1.21%) ▲|TSLA394.18-13.58 (-3.33%) ▼|TXN303.12-8.34 (-2.68%) ▼|UBER75.04+0.50 (+0.67%) ▲|UNH430.47+5.85 (+1.38%) ▲|UNP289.20+2.24 (+0.78%) ▲|UPS113.89+1.42 (+1.26%) ▲|USB62.26-0.16 (-0.25%) ▼|V354.82+5.85 (+1.67%) ▲|VZ42.57+0.45 (+1.06%) ▲|WFC86.64-0.53 (-0.60%) ▼|WMT114.99+1.09 (+0.95%) ▲|XOM142.38+3.50 (+2.52%) ▲|AAPL321.61+6.29 (+1.99%) ▲|ABBV247.78-0.31 (-0.12%) ▼|ABT92.38-1.55 (-1.65%) ▼|ACN136.61+1.38 (+1.02%) ▲|ADBE227.17+3.53 (+1.58%) ▲|AMAT579.00-23.50 (-3.90%) ▼|AMD533.01-24.88 (-4.46%) ▼|AMGN359.68-3.71 (-1.02%) ▼|AMT169.91+1.32 (+0.78%) ▲|AMZN246.52+1.18 (+0.48%) ▲|AVGO390.93-9.05 (-2.26%) ▼|AXP355.80+5.22 (+1.49%) ▲|BA217.87-4.42 (-1.99%) ▼|BAC59.06-0.62 (-1.03%) ▼|BKNG176.69-1.70 (-0.95%) ▼|BLK1,026.15-9.96 (-0.96%) ▼|BMY58.48+0.90 (+1.55%) ▲|BNY150.54-1.38 (-0.91%) ▼|BRK-B499.05+5.34 (+1.08%) ▲|C138.54-2.25 (-1.60%) ▼|CAT938.96-13.46 (-1.41%) ▼|CL93.47+1.23 (+1.33%) ▲|CMCSA24.10+0.53 (+2.23%) ▲|COF203.45+1.93 (+0.96%) ▲|COP111.34+2.30 (+2.11%) ▲|COST919.22+2.97 (+0.32%) ▲|CRM166.51+3.19 (+1.95%) ▲|CSCO118.05-3.26 (-2.69%) ▼|CVS106.10+1.95 (+1.87%) ▲|CVX179.77+3.37 (+1.91%) ▲|DE583.31-3.56 (-0.61%) ▼|DHR199.62+0.57 (+0.29%) ▲|DIS97.22+1.60 (+1.67%) ▲|DUK126.93+1.45 (+1.16%) ▲|EMR138.32-0.57 (-0.41%) ▼|FDX314.44-0.25 (-0.08%) ▼|GD375.81+0.75 (+0.20%) ▲|GE356.69-2.58 (-0.72%) ▼|GEV1,062.11-29.47 (-2.70%) ▼|GILD129.23-0.61 (-0.47%) ▼|GM77.71-0.15 (-0.19%) ▼|GOOG353.36-1.68 (-0.47%) ▼|GOOGL355.78-1.40 (-0.39%) ▼|GS1,052.16-3.02 (-0.29%) ▼|HD343.29-0.01 (0.00%) ▼|HON222.88-3.55 (-1.57%) ▼|IBM292.22+4.66 (+1.62%) ▲|INTC105.02-4.82 (-4.39%) ▼|INTU284.76+9.80 (+3.56%) ▲|ISRG412.72+5.94 (+1.46%) ▲|JNJ257.41+0.43 (+0.17%) ▲|JPM334.44-2.03 (-0.60%) ▼|KO84.18+0.69 (+0.83%) ▲|LIN526.02-3.77 (-0.71%) ▼|LLY1,189.15+0.57 (+0.05%) ▲|LMT520.15-3.08 (-0.59%) ▼|LOW212.21+0.58 (+0.27%) ▲|LRCX333.32-17.01 (-4.86%) ▼|MA534.50+7.76 (+1.47%) ▲|MCD274.49-0.12 (-0.04%) ▼|MDLZ60.47+1.64 (+2.79%) ▲|MDT84.40+0.53 (+0.63%) ▲|META663.80-5.41 (-0.81%) ▼|MMM158.57+1.05 (+0.67%) ▲|MO72.74+0.95 (+1.32%) ▲|MRK123.71+0.17 (+0.14%) ▲|MS220.66-1.62 (-0.73%) ▼|MSFT385.60+0.50 (+0.13%) ▲|MU930.45-48.86 (-4.99%) ▼|NEE88.39+0.43 (+0.48%) ▲|NFLX75.22+1.85 (+2.51%) ▲|NKE44.45+0.08 (+0.17%) ▲|NOW108.55+0.84 (+0.78%) ▲|NVDA209.34-1.62 (-0.77%) ▼|ORCL136.14-4.51 (-3.20%) ▼|PEP139.75+2.37 (+1.73%) ▲|PFE24.63+0.46 (+1.88%) ▲|PG149.10+2.06 (+1.40%) ▲|PLTR128.28+1.49 (+1.18%) ▲|PM182.80+1.18 (+0.65%) ▲|QCOM186.37-2.79 (-1.47%) ▼|RTX195.83-0.10 (-0.05%) ▼|SBUX107.98+1.97 (+1.86%) ▲|SCHW102.72-0.40 (-0.39%) ▼|SO96.63+1.02 (+1.06%) ▲|SPG221.45+2.68 (+1.22%) ▲|T21.44+0.31 (+1.44%) ▲|TMO528.36+1.31 (+0.25%) ▲|TMUS189.88+2.27 (+1.21%) ▲|TSLA394.18-13.58 (-3.33%) ▼|TXN303.12-8.34 (-2.68%) ▼|UBER75.04+0.50 (+0.67%) ▲|UNH430.47+5.85 (+1.38%) ▲|UNP289.20+2.24 (+0.78%) ▲|UPS113.89+1.42 (+1.26%) ▲|USB62.26-0.16 (-0.25%) ▼|V354.82+5.85 (+1.67%) ▲|VZ42.57+0.45 (+1.06%) ▲|WFC86.64-0.53 (-0.60%) ▼|WMT114.99+1.09 (+0.95%) ▲|XOM142.38+3.50 (+2.52%) ▲|
26.9 C
New York
Monday, July 13, 2026

Tag: value

newssourceFORcompanyinformationcontent1releasesmarket

ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent for Clear Cell Renal...


Garching / Munich, Germany, and Lausanne, Switzerland - June 23, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and Debiopharm, a Swiss-based, global biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced that the first patient was imaged in a new study arm of a five-part, Phase 1/2 clinical trial (formerly GaLuCi™) (NCT05706129) evaluating the theranostic pair ITM-94/ITM-91 for identification and treatment of patients who have unresectable, locally advanced or metastatic solid tumors. As a new component of a broad clinical development plan for ITM-91/ITM-94, Part D of the trial will evaluate the effectiveness of ITM-94 in classifying indeterminate renal mass as either ccRCC or non-cancerous.

E-Invoicing Could Unlock Nearly £9 Billion for the UK Economy, Avalara Finds

New global research from Avalara and Cebr reveals the transformative power of electronic invoicing adoption in the UK and across five other major marketsProductivity...

E-Invoicing Could Unlock $116 Billion for the U.S. Economy & $616 Billion Globally, Avalara Finds

New global research from Avalara and Cebr reveals the transformative power of electronic invoicing adoption in the U.S. and across five other major markets...

Danske Bank share buy-back programme: transactions in week 25

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Herspiegel Acquires Decisive Consulting to Expand Global Life Sciences Commercialization Services

Blending Bold Strategy with Proven Market Access and Health Economics Expertise to Unlock Asset Value YARDLEY, Pa. and LONDON, June 23, 2025 /PRNewswire/ -- Herspiegel,...

WBBA Broadband Development Congress Shanghai 2025 | Smarter Infrastructure: Converging AI and Broadband

SHANGHAI, June 23, 2025 /PRNewswire/ -- The World Broadband Association (WBBA) successfully convened the 2025 Broadband Development Congress in Shanghai, spotlighting the theme: "Smarter...

Eddid Financial and EXIO Limited Forge Strategic Partnership To Drive Virtual Asset Market Growth

HONG KONG, June 23, 2025 /PRNewswire/ -- Eddid Financial, a leading fintech-driven financial services group, and EXIO Limited, a licensed virtual asset trading platform...

Kao Indonesia Celebrates 40 Years of Thoughtful Innovation with the Launch of Biore Breeze Deodorant

Kao Indonesia reflects on four decades of thoughtful innovation and social impact, championing the values of cleanliness, beauty, and harmonious living, Kirei. With the...

Antonio Filosa Announces New Stellantis Leadership Team on First Day as CEO

AMSTERDAM, June 23, 2025 /PRNewswire/ -- Antonio Filosa today takes up the role as Chief Executive Officer of Stellantis N.V. and announces his new...

Share repurchase programme: Transactions of week 25 2025

The share repurchase programme runs as from 26 February 2025 and up to and including 30 January 2026 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 2.25 billion, cf. Corporate Announcement No. 3/2025 of 26 February 2025. The share repurchase programme is initiated and structured in compliance with the EU Commission Regulation No. 596/2014 of 16 April 2014, the so-called “Market Abuse Regulation”, and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the "Safe Harbour Rules").

WySE Products Launches Total Pet Kitchen, The First-of-Its-Kind Multicooker for Fresh Pet Food Preparation at Home

Englewood Cliffs, NJ, June 23, 2025 (GLOBE NEWSWIRE) -- WySE Products LLC, a company committed to redefining pet nutrition, is pleased to announce the launch of Total Pet Kitchen Multicooker (TPK), the first-of-its-kind countertop appliance designed specifically for cooking and dispensing healthy food for pets using human-grade ingredients.

Navamedic ASA expands into addiction treatment through the acquisition of the business of dne pharma and announces a partially underwritten rights issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE...

Yili Secures Four World Dairy Innovation Awards at the 18th Global Dairy Congress

AMSTERDAM, June 23, 2025 /PRNewswire/ -- On June 18–19, the Global Dairy Congress 2025 was held in Amsterdam. At the forum, Dr. Ignatius Szeto, Assistant President...

From Wildlife Detection to Search & Rescue Missions: Raytron’s Thermal Cameras Enhance Outdoor Adventures Safety

YANTAI, China, June 23, 2025 /PRNewswire/ -- As interest in hiking, mountaineering and camping continues to surge, outdoor enthusiasts face the perennial challenge of navigating...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsValue

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers